Regeneron's 2025 outlook includes defensive capital allocation, competitive pressure on Eylea, et cetera. Click here to read ...

RBC Capital lowered the firm’s price target on Regeneron (REGN) to $1,045 from $1,059 but keeps an Outperform rating on the shares. The ...

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...

China, one of the countries affected by the new tariffs, is the world’s largest producer of active pharmaceutical ingredients ...